Pipeline PDF Print E-mail

We are advancing our clinical pipeline of first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer. This new class of phosphatidylserine (PS)-targeting antibodies target and bind to PS, a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, causing the tumor to evade immune detection. Bavituximab is our lead therapeutic PS-targeting antibody candidate, which has demonstrated broad therapeutic potential and represents a new approach to treating cancer. PGN650 is our lead PS-targeting imaging agent that represents a potential new approach to imaging cancer. Bavituximab targets PS and works by activating the immune system causing the maturation of cancer-fighting (M1) macrophages and the development of cytotoxic T-cells that fight solid tumors. Learn about bavituximab's mechanism of action.

 

Products under investigation have not been approved for use outside the clinical trial setting. This information is presented only for the purposes of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes. ©2014 Peregrine Pharmaceuticals, Inc. All rights reserved.